Pyxis Oncology Statistics
Total Valuation
Pyxis Oncology has a market cap or net worth of $68.76 million. The enterprise value is -$16.83 million.
Important Dates
The last earnings date was Thursday, May 15, 2025, before market open.
Earnings Date | May 15, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Pyxis Oncology has 61.95 million shares outstanding. The number of shares has increased by 38.73% in one year.
Current Share Class | 61.95M |
Shares Outstanding | 61.95M |
Shares Change (YoY) | +38.73% |
Shares Change (QoQ) | -0.32% |
Owned by Insiders (%) | 6.29% |
Owned by Institutions (%) | 32.69% |
Float | 44.65M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 0.66 |
P/TBV Ratio | 0.68 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.75, with a Debt / Equity ratio of 0.19.
Current Ratio | 7.75 |
Quick Ratio | 7.31 |
Debt / Equity | 0.19 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -66.30% and return on invested capital (ROIC) is -31.70%.
Return on Equity (ROE) | -66.30% |
Return on Assets (ROA) | -29.19% |
Return on Invested Capital (ROIC) | -31.70% |
Return on Capital Employed (ROCE) | -68.48% |
Revenue Per Employee | n/a |
Profits Per Employee | -$2.16M |
Employee Count | 44 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | -2.16M |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -73.57% in the last 52 weeks. The beta is 1.15, so Pyxis Oncology's price volatility has been higher than the market average.
Beta (5Y) | 1.15 |
52-Week Price Change | -73.57% |
50-Day Moving Average | 1.06 |
200-Day Moving Average | 2.28 |
Relative Strength Index (RSI) | 51.79 |
Average Volume (20 Days) | 564,644 |
Short Selling Information
The latest short interest is 7.23 million, so 11.68% of the outstanding shares have been sold short.
Short Interest | 7.23M |
Short Previous Month | 7.13M |
Short % of Shares Out | 11.68% |
Short % of Float | 16.20% |
Short Ratio (days to cover) | 13.60 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -83.16M |
Pretax Income | -57.80M |
Net Income | -95.23M |
EBITDA | -80.55M |
EBIT | -83.16M |
Earnings Per Share (EPS) | -$1.57 |
Full Income Statement Balance Sheet
The company has $105.43 million in cash and $19.84 million in debt, giving a net cash position of $85.59 million or $1.38 per share.
Cash & Cash Equivalents | 105.43M |
Total Debt | 19.84M |
Net Cash | 85.59M |
Net Cash Per Share | $1.38 |
Equity (Book Value) | 103.10M |
Book Value Per Share | 1.69 |
Working Capital | 97.44M |
Full Balance Sheet Cash Flow
Operating Cash Flow | n/a |
Capital Expenditures | n/a |
Free Cash Flow | n/a |
FCF Per Share | n/a |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |